human
respiratori
syncyti
viru
hrsv
highli
contagi
paramyxoviru
infect
children
age
two
gener
estim
hospit
us
annual
hrsv
common
caus
bronchiol
pneumonia
among
infant
children
year
age
signific
mortal
among
highrisk
group
regulatori
agencyapprov
vaccin
avail
exist
prophylaxi
therapi
limit
use
highrisk
pediatr
patient
thu
addit
therapi
sore
need
identifi
seri
benzimidazol
analog
inhibit
hrsv
infect
vitro
high
potenc
use
previouslyreport
highthroughput
screen
assay
lead
compound
sri
triazolo
le
ec
lm
select
identifi
addit
compound
vari
potenc
test
commerciallyavail
chemic
analog
timeofaddit
experi
indic
sri
effect
inhibit
viral
replic
present
earli
stage
viral
infect
isol
viru
resist
sri
identifi
mutat
transmembran
domain
viral
g
protein
genom
sequenc
suggest
compound
inhibit
gprotein
mediat
attach
hrsv
cell
addit
experi
multipl
cell
type
indic
sri
antivir
activ
correl
bind
cell
surfac
heparin
fulllength
g
protein
lastli
sri
reduc
hrsv
titer
morbiditymort
efficaci
studi
use
cotton
rat
model
although
sri
analog
inhibit
hrsv
replic
vitro
work
suggest
gprotein
may
valid
drug
target
vivo
human
rsv
hrsv
belong
famili
paramyxovirida
import
caus
infecti
pulmonari
diseas
human
infant
major
caus
agent
respiratori
tract
infect
among
children
worldwid
u
estim
indirect
direct
impact
hospit
due
hrsv
infect
million
palmer
et
al
infant
immunecompromis
children
underli
respiratori
disord
significantli
higher
risk
develop
sever
hrsv
infect
complic
opportunist
viral
pneumonia
respiratori
distress
elderli
immunecompromis
individu
also
suscept
complic
hrsv
infect
therebi
highlight
import
medic
intervent
form
prophylact
antivir
therapi
byrd
princ
exist
prophylaxi
antivir
therapi
acut
hrsv
infect
infant
limit
human
monoclon
antibodi
reserv
use
high
risk
pediatr
patient
ribavirin
olszewska
openshaw
multipl
potenti
antivir
clinic
investig
pryde
et
al
yu
et
al
yu
et
al
includ
two
current
clinic
trial
nucleosid
rna
polymeras
inhibitor
wang
et
al
fusion
inhibitor
mackman
et
al
howev
none
approv
govern
agenc
therapi
avail
research
commun
tool
studi
life
cycl
viru
hostviru
interact
therefor
signific
research
medic
need
met
discoveri
addit
probe
potenti
therapeut
hrsv
hrsv
neg
sens
singlestrand
nonseg
rna
viru
genom
approxim
kb
ten
viral
gene
http
elsevi
bv
right
reserv
encod
viral
protein
inhibit
type
interferon
activ
n
nucleocapsid
protein
encod
matrix
protein
sh
g
f
fusion
protein
incorpor
viral
coat
g
protein
posttransl
glycosyl
surfac
protein
also
recogn
cell
surfac
compon
eg
heparin
viral
attach
f
protein
mediat
entri
viru
cell
cytoplasm
also
promot
format
syncytia
typic
antibodi
direct
f
protein
neutral
protein
conserv
subtyp
rsv
g
protein
vari
sequenc
consider
hrsv
b
subtyp
gene
encod
elong
factor
transcript
factor
l
gene
encod
viral
rna
polymeras
phosphoprotein
p
cofactor
l
function
olszewska
openshaw
studi
use
vitro
infect
model
hrsv
cell
search
chembridg
small
molecul
librari
lead
therapeut
antivir
candid
identifi
character
seri
compound
inhibit
hrsv
replic
vitro
develop
mutant
viru
resist
lead
inhibitor
compound
sequenc
mutant
viru
identifi
mutat
nterminu
viral
g
protein
implic
g
protein
target
compound
inhibit
experi
multipl
cell
line
vero
indic
lead
compound
effect
cell
line
express
high
percentag
fulllength
g
protein
suggest
compound
target
viral
g
protein
howev
vivo
studi
lead
compound
reduc
viral
titer
extend
live
cotton
rat
lethal
hrsv
challeng
model
data
suggest
target
function
g
protein
small
molecul
inhibitor
effect
inhibit
hrsv
replic
vitro
strategi
cell
typedepend
may
viabl
therapeut
intervent
vivo
inhibit
cell
death
cytopath
effect
cpe
caus
hrsv
infect
cell
use
primari
assay
identifi
antivir
effect
compound
screen
cell
hrsv
strain
purchas
american
tissu
cultur
type
manassa
va
cell
atcc
cell
atcc
vero
cell
atcc
cultur
penstreplglutamin
invitrogen
grand
island
ny
cell
maintain
adher
cell
line
humidifi
co
atmospher
passag
need
harvest
flask
use
trypl
gibco
human
respiratori
syncyti
viru
strain
long
atcc
purchas
amplifi
studi
viru
cultur
media
penstreplglutamin
viru
stock
supplier
dilut
ad
flask
contain
viru
cultur
media
flask
incub
co
rel
humid
h
viru
cultur
media
transfer
ml
conic
tube
cell
debri
pellet
rpm
min
fb
ad
final
concentr
vv
preserv
supernat
aliquot
ml
per
tube
flashfrozen
dri
icemethanol
store
amplif
viru
stock
titer
quantifi
cell
serial
dilut
determin
tcid
titer
viru
tcid
ml
tcid
viru
determin
use
ten
halflogfold
serial
dilut
microtitr
assay
cell
plate
plate
cellswel
infect
serial
dilut
hrsv
microtitr
plate
incub
co
rel
humid
four
day
tcid
cultur
viru
stock
determin
cell
viabil
assay
measur
extent
virusinduc
cell
death
cytopath
effect
cpe
presenc
concentr
rang
test
compound
noah
et
al
hrsv
cell
use
assay
cell
plate
plate
analysi
cpe
test
compound
ad
immedi
infect
present
throughout
infect
standard
antivir
assay
test
well
viru
control
well
receiv
tcid
hrsv
moi
test
compound
cytotox
assay
parallel
well
compound
concentr
without
addit
viru
four
day
later
cell
viabil
well
determin
concentr
test
compound
reduc
virusinduc
cpe
ec
calcul
cytotox
concentr
test
compound
reduc
cell
number
cc
determin
select
index
compound
si
cc
ec
calcul
unless
otherwis
state
experi
perform
triplic
titer
reduct
assay
measur
differ
viral
titer
nontreat
test
compoundtr
cell
compound
inhibit
viral
replic
result
reduct
progeni
viru
compar
viru
cell
control
vero
cell
infect
hrsv
long
strain
mutant
hrsv
moi
presenc
lm
sri
viral
titer
calcul
use
tcid
method
noah
et
al
statist
analysi
data
perform
use
ttest
twosampl
assum
equal
varianc
differ
tcid
valu
wt
resist
mutant
virus
presenc
sri
sampl
perform
quadrupl
follow
four
day
incub
period
assay
plate
equilibr
room
temperatur
min
equal
volum
cell
titerglo
reagent
promega
inc
madison
wi
ad
micropl
well
plate
incub
addit
min
room
temperatur
noah
et
al
measur
hrsvinduc
cpe
base
quantit
atp
indic
metabol
activ
cell
procedur
involv
ad
singl
reagent
celltiterglo
reagent
directli
previous
cultur
subconflu
cell
media
induc
cell
lysi
product
bioluminesc
signal
halflif
greater
h
depend
cell
type
proport
amount
atp
present
biomark
viabil
test
plate
read
luminesc
perkin
elmer
envis
multilabel
plate
reader
perkin
elmer
waltham
massachusett
integr
time
sri
lm
ad
plate
contain
cell
timepoint
h
postvir
infect
cell
cell
infect
timepoint
zero
hour
moi
tcid
hrsv
long
strain
follow
fourday
incub
period
celltiterglo
reagent
ad
describ
percentag
viabl
cell
rel
uninfect
control
calcul
time
point
determin
timepoint
compound
addit
longer
sustain
cell
viabil
hrsv
long
strain
passag
micropl
presenc
doubl
concentr
lm
sri
five
passag
amplifi
addit
five
passag
presenc
lm
sri
cultur
passag
pool
dilut
use
inocul
subsequ
cultur
control
hrsv
long
strain
also
passag
absenc
sri
number
passag
end
ten
passag
wt
put
mutant
virus
amplifi
one
addit
time
flask
harvest
aliquot
storag
analysi
sri
lm
includ
mutant
viru
amplif
sequenc
ml
viru
cultur
use
isol
viral
rna
phenol
ether
ethanol
precipit
crna
produc
superscript
iii
onestep
rtpcr
system
life
technolog
sequenc
cdna
strand
perform
use
primer
report
rebuffosch
et
al
compound
analog
purchas
chembridg
san
diego
ca
mg
sampl
dissolv
dmso
concentr
mm
stock
use
antivir
test
vivo
studi
perform
evalu
effect
dosag
antivir
efficaci
sri
administ
h
intraperiton
inject
respiratori
syncyti
viru
rsv
cotton
rat
cr
model
endpoint
studi
demonstr
reduc
viru
titer
lung
lavag
ml
nasal
wash
ml
fluid
treat
infect
cotton
rat
ca
g
weight
compar
vehicletr
infect
cotton
rat
viru
quantif
done
plaqu
reduct
assay
serum
sampl
obtain
time
infect
time
sacrific
cotton
rat
bodi
weight
record
end
experi
day
anim
bodi
weight
sex
distribut
select
similar
possibl
across
group
start
rsvatraci
passag
three
grown
cell
pfu
intranas
cotton
rat
lightli
anesthet
isofluran
stock
viru
concentr
pfuml
compound
sri
mg
chembridg
san
diego
ca
suppli
dri
powder
dilut
ml
pb
mgml
prepar
vortex
sonic
water
bath
solut
appear
clear
min
sonic
solut
appear
emuls
emuls
use
ip
inject
aliquot
store
dose
volum
mlkg
kg
cotton
rat
plaqu
assay
perform
use
tissu
cultur
plate
contain
nearli
confluent
monolay
cellswel
cell
prepar
fb
h
prior
start
assay
start
assay
dilut
usual
serial
log
made
test
sampl
ml
sampl
ad
well
duplic
allow
adsorb
min
occasion
gentl
agit
inoculum
remov
monolay
overlay
methylcellulos
fbsmem
contain
antibiot
vitamin
nutrient
tissu
cultur
posit
viru
control
includ
assay
plate
place
co
incub
day
plate
stain
crystal
formalin
solut
mlwell
allow
sit
h
room
temperatur
well
rins
water
visibl
plaqu
count
plaqu
well
contain
plaqu
enumer
averag
viru
titer
calcul
total
log
pfu
nasal
wash
fluid
log
pfug
tissu
lung
lower
limit
detect
method
log
total
pfu
approxim
log
pfug
lung
respect
previous
publish
report
detail
develop
perform
hrsv
highthroughput
screen
identif
hit
compound
deriv
screen
nih
molecular
librari
chemic
collect
screen
assay
format
use
screen
compound
chembridg
small
molecul
librari
chembridg
select
compound
ec
valu
lm
select
indic
si
hit
primari
confirmatori
screen
result
confirm
hit
ec
rang
lm
si
rang
compound
character
select
base
potenc
previou
character
reactiv
tractabl
chemic
optim
compound
character
previou
hrsv
screen
campaign
matharu
et
al
moor
et
al
character
potent
novel
confirm
compound
ht
screen
triazolo
structur
shown
tabl
compound
previous
report
effect
hrsv
design
sri
base
confirm
potent
vitro
antivir
activ
lack
previouslyreport
antivir
activ
ant
potenti
chemic
modif
sri
chosen
character
determin
ec
cc
si
structureact
relationship
broad
antivir
activ
mechan
action
vivo
potenc
determin
ec
sri
concentr
rang
compound
lm
ad
cell
cell
immedi
infect
tcid
hrsv
compound
cytotox
experi
viru
perform
parallel
identifi
compound
cc
fig
show
concentrationdepend
effect
sri
virusinduc
cpe
cell
viabil
cell
ec
valu
lm
cell
respect
si
valu
respect
ec
si
valu
sri
cell
also
indic
tabl
antivir
efficaci
sri
rna
virus
explor
use
addit
vitro
cpe
assay
model
compound
test
human
metapneumoviru
nipah
viru
paromyxovirus
venezuelan
equin
enceph
viru
alphaviru
dengu
viru
flaviviru
human
influenza
viru
orthomyxoviru
sar
cov
coronaviru
signific
reduct
cpe
due
antivir
activ
observ
virus
defin
structureact
relationship
sri
commerciallyavail
compound
structur
similar
sri
purchas
test
cpe
assay
efficaci
hrsv
cell
compound
reduc
virusinduc
cpe
ec
valu
rang
lm
enabl
structureact
relationship
determin
compound
shown
tabl
effect
reduc
rsvinduc
cpe
hep
cell
two
high
activ
si
five
moder
activ
si
ten
low
activ
si
structur
varianc
occur
posit
r
r
signific
differ
compound
potenc
observ
chang
posit
tabl
structureact
relationship
analysi
indic
carbon
atom
r
posit
favor
imin
posit
compound
potent
compound
compound
greatest
potenc
lowest
ec
highest
si
indic
thiofuran
r
posit
potent
furan
compound
substitut
r
aromat
ring
substitut
result
even
less
potent
compound
compound
modif
aromat
ring
halogen
chlorin
fluorin
decreas
potenc
benzimidazol
scaffold
analog
stabl
assay
condit
storag
dmso
gener
manipul
sri
structur
contain
moieti
known
gener
reactiv
timeofaddit
experi
perform
determin
stage
hrsv
replic
cycl
inhibit
sri
use
moi
tcid
cell
infect
hrsv
sri
lm
ad
design
time
point
cpe
measur
h
postinfect
fig
show
sri
prevent
cpe
ad
h
postinfect
addit
sri
h
postinfect
prevent
greater
virusinduc
cpe
indic
compound
inhibit
earli
step
within
first
h
viru
replic
cycl
sequenti
passag
wildtyp
viru
select
pressur
increas
concentr
sri
result
develop
viru
resist
antivir
effect
sri
resist
viru
plaqu
purifi
amplifi
cell
presenc
lm
sri
character
howev
titrat
experi
resist
viru
establish
ec
fig
like
resist
mutant
viru
resist
wt
viru
ec
concentr
sri
select
sri
compoundinduc
cc
ec
valu
mutant
viru
howev
high
resist
mutant
hrsv
viru
subcultur
amplifi
presenc
lm
sri
stock
viru
prepar
store
viral
rna
ml
amplifi
mutant
viru
cultur
isol
cdna
reversetranscrib
use
hrsvspecif
primer
complet
mutant
viru
genom
sequenc
twice
mutat
identifi
viral
g
protein
gene
suggest
antivir
mechan
sri
associ
hrsv
g
protein
function
fig
b
depict
region
viral
g
protein
genet
sequenc
contain
mutat
locat
mutat
primari
protein
domain
structur
viral
g
protein
even
multipl
passag
compound
select
mix
popul
wt
mutant
observ
g
protein
genet
sequenc
viru
still
resist
sri
wt
hrsv
mutat
occur
ntermin
region
g
protein
within
transmembran
domain
fig
show
extend
amino
acid
sequenc
transmembran
domain
surround
point
mutat
region
contain
mutat
conserv
rsva
strain
long
rsva
strain
traci
use
vivo
studi
describ
rsvb
sri
test
rsvb
viral
g
protein
mediat
viru
attach
bind
heparin
molecul
express
cell
surfac
krusat
streckert
requir
fulllength
g
protein
effici
previous
shown
virusassoci
express
fulllength
g
protein
cell
cultur
factor
cell
type
kwila
et
al
viral
replic
cell
result
express
fulllength
g
protein
kda
wherea
replic
cell
vero
cell
result
express
truncat
g
protein
kda
miss
cterminu
replic
hrsv
cell
depend
bind
g
protein
cell
surfac
heparin
glycosaminoglycan
howev
replic
cell
vero
cell
produc
hrsv
infect
cell
heparinindepend
mechan
like
truncat
g
protein
contain
fulli
function
heparin
bind
domain
kwila
et
al
use
celldepend
differ
express
g
protein
length
measur
antivir
efficaci
sri
three
differ
cell
type
determin
compound
effect
hrsv
fulllength
g
protein
three
cell
type
infect
wildtyp
sri
hrsv
mutant
presenc
lm
sri
reduct
viru
tcid
reduct
assay
determin
fig
show
compoundmedi
reduct
viral
titer
wt
mutant
viru
vero
cell
rel
infect
compound
control
wt
hrsv
compound
reduc
viru
tcid
valu
p
p
cell
less
p
vero
cell
antivir
activ
sri
wt
hrsv
celltyp
specif
strongli
correl
express
fulllength
g
protein
implic
g
protein
compound
target
mutant
hrsv
compound
reduc
viru
tcid
valu
less
cell
type
furthermor
presenc
sri
log
reduct
wt
hrsv
titer
v
log
reduct
compoundresist
hrsv
titer
observ
cell
howev
reduc
titer
virus
less
log
vero
cell
indic
compound
littl
effect
either
wt
mutant
viru
titer
truncat
g
protein
express
fig
ec
cc
plot
sri
cell
ec
cc
valu
calcul
sri
wt
hrsv
either
cell
b
cell
panel
c
concentrationdepend
antivir
cytotox
respons
calcul
sri
wt
hrsv
cell
eight
point
concentr
dose
respons
cytoprotect
assay
perform
compound
concentr
rang
lgml
presenc
hrsvinfect
cell
percent
cell
viabil
compar
uninfect
undrug
cell
control
plot
v
test
compound
concentr
solid
line
concentr
point
perform
triplic
parallel
concentr
rang
test
compound
ad
uninfect
cell
determin
compoundinduc
cytotox
dot
line
ec
cc
valu
convert
log
molar
concentr
xaxi
doserespons
curv
plot
ec
valu
calcul
use
idb
xlfit
function
b
cx
minimum
maximum
b
paramet
set
respect
fourday
incub
cell
viabil
determin
compar
uninfect
undrug
cell
control
n
graph
show
chang
cell
viabil
compound
addit
timepoint
chang
demonstr
sri
reduc
cpe
ad
h
postinfect
cotton
rat
model
hrsv
strain
atraci
use
test
vivo
potenc
sri
vitro
potenc
rsva
traci
determin
administr
sri
infect
anim
result
signific
differ
observ
lung
lobe
weight
bodi
weight
rsv
titer
nasal
wash
lung
lavag
fluid
vitro
pharmacokinet
sri
partial
investig
aqueou
media
solubl
determin
um
aqueou
stabil
halflif
measur
h
cell
cultur
media
clogp
compound
complet
solubl
concentr
use
high
dose
may
account
lack
vivo
activ
howev
lack
vivo
activ
lower
dose
suggest
sri
effect
inhibit
viral
replic
vivo
although
hrsv
identifi
decad
ago
current
approv
vaccin
first
vaccin
test
studi
caus
diseas
enhanc
sever
bronchiol
pneumonia
requir
hospit
vaccin
children
hrsv
challeng
two
infant
death
delgado
et
al
duda
karron
karron
et
al
result
develop
vaccin
proceed
slowli
great
caution
approv
therapi
viral
infect
ribavirin
pelaez
et
al
prophylact
human
monoclon
antibodi
synagi
palivizumab
administ
high
risk
pediatr
patient
infect
immunocompromis
patient
ridki
newer
potenti
therapeut
investig
review
elsewher
mackman
et
al
olszewska
openshaw
wang
et
al
fact
none
approv
regulatori
agenc
due
econom
clinic
test
complex
underscor
need
renew
search
novel
effect
safe
antivir
effect
hrsv
use
vitro
ht
cytoprotect
assay
identifi
lead
compound
sri
effect
protect
sri
differenti
efficaci
vero
cell
confluent
monolay
vero
cell
either
rsva
long
strain
wildtyp
mutant
presenc
lm
sri
reduct
viru
titer
tcid
reduct
determin
rel
infect
compound
control
cell
n
compound
reduc
wt
hrsv
viru
valu
cell
less
vero
cell
sri
reduc
mutant
hrsv
viru
tcid
valu
less
cell
type
cell
hrsvinduc
cpe
establish
compound
ec
select
use
chemic
analog
sri
determin
structur
activ
relationship
use
vitro
assay
sri
effect
rna
virus
timeofaddit
experi
indic
sri
reduc
hrsvinduc
cpe
ad
within
h
viru
infect
suggest
inhibit
earli
viru
replic
step
hrsv
mutant
resist
inhibit
compound
isol
sequenc
mutat
identifi
sequenc
viral
g
protein
implic
g
protein
put
target
inhibit
vitro
character
wt
mutant
virus
cell
type
express
either
fulllength
truncat
g
protein
suggest
sri
inhibit
viral
g
protein
function
lastli
vivo
studi
perform
determin
effect
compound
reduc
hrsv
titer
challeng
cotton
rat
sri
larg
insolubl
chosen
dose
formul
effect
reduc
hrsv
titer
patholog
anim
model
specif
cell
surfac
receptor
use
infect
hrsv
known
cell
surfac
glycosaminoglycan
particular
heparan
sulfat
shown
import
infect
schlender
et
al
hrsv
g
protein
type
ii
transmembran
glycoprotein
major
hrsv
attach
protein
kauvar
et
al
role
nomin
attach
protein
g
confin
facilit
infect
nonspeciesspecif
manner
probabl
bind
cell
surfac
glycosaminoglycan
kauvar
et
al
contain
singl
hydrophob
region
serv
signal
peptid
also
membran
anchor
rsv
g
protein
also
import
contributor
diseas
process
conserv
chemokin
like
motif
g
like
contribut
pathogenesi
diseas
harcourt
et
al
g
protein
evolutionarili
conserv
strain
rsv
central
conserv
cystein
noos
region
contain
chemokin
motif
amino
acid
posit
harcourt
et
al
motif
g
protein
bind
present
variou
immun
cell
affect
immun
respons
hrsv
shown
mous
model
rsv
infect
howev
littl
known
role
rsv
interact
human
diseas
report
suggest
hrsv
g
protein
motif
impair
innat
adapt
human
immun
respons
may
import
vaccin
antivir
drug
develop
chirkova
et
al
lastli
vaccin
motif
induc
protect
immun
respons
mice
jorquera
et
al
identifi
compound
inhibit
viral
replic
put
mechan
interf
function
viral
g
protein
sinc
g
protein
bind
cell
surfac
heparin
molecul
viru
attach
one
possibl
mechan
sri
action
inhibit
g
proteinmedi
heparin
bind
demonstr
antivir
efficaci
test
compound
sri
wt
hrsv
significantli
reduc
cell
type
ie
vero
express
truncat
g
protein
depend
heparin
bind
infect
also
show
presenc
sri
phenotyp
wt
mutant
hrsv
differ
cell
similar
vero
cell
suggest
truncat
g
protein
possibl
loss
heparinbind
domain
link
compound
mechan
action
although
hrsv
primarili
infect
cell
heparin
bind
domain
g
protein
mutant
knockout
virus
lack
g
gene
still
infect
cell
replic
vitro
vivo
presum
attach
redund
heparin
bind
domain
f
protein
karron
et
al
observ
reciproc
vivo
studi
sri
significantli
reduc
hrsv
titer
patholog
cotton
rat
infect
model
overal
compound
serv
excel
vitro
inhibitor
hrsv
replic
effect
vivo
rsva
strain
traci
sinc
residu
conserv
rsva
long
traci
strain
expect
compound
would
effect
rsva
traci
lack
vivo
confirm
vitro
activ
may
result
compound
formul
may
indic
viral
g
protein
function
valid
drug
target
small
molecul
therapi
might
due
state
observ
hrsv
g
protein
knockout
virus
still
infect
suffici
efficaci
support
robust
viru
replic
lastli
residu
conserv
b
strain
rsvb
residu
isoleucin
unclear
whether
would
suscept
inhibit
sequenc
alon
research
conduct
complianc
anim
welfar
act
feder
statut
regul
relat
anim
experi
involv
anim
adher
principl
state
nation
research
council
nation
academi
guid
care
use
laboratori
anim
facil
research
conduct
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
